利妥昔单抗时代套细胞淋巴瘤患者的生存:2000年至2020年回顾性双国分析
该回顾性双国队列纳入2000年至2020年间诊断和治疗的564例套细胞淋巴瘤患者,数据来自7个芬兰治疗中心和1个西班牙治疗中心。全队列2年总生存率为77%、5年总生存率为58%、10年总生存率为32%,估计中位总生存期为80个月。基于首次复发后生存的统计分析,初始诊断后24个月内疾病进展应被视为预后不良的强指标。
要点
- 全队列2年总生存率77%、5年58%、10年32%,估计中位总生存期80个月。
- 套细胞淋巴瘤在全患者人群中与死亡率增加相关。
- 初始诊断后24个月内疾病进展应被视为预后不良的强指标。
核心结论
- 套细胞淋巴瘤在全患者人群中与死亡率增加相关。
- 基于首次复发后生存的统计分析,初始诊断后24个月内疾病进展应被视为预后不良的强指标。
研究设计与样本
- 回顾性双国队列分析,纳入2000年至2020年间诊断和治疗的564例套细胞淋巴瘤患者。
- 患者数据来自7个芬兰治疗中心和1个西班牙治疗中心。
主要发现
- 全患者人群2年总生存率为77%,5年总生存率为58%,10年总生存率为32%。
- 估计中位总生存期为诊断后80个月。
关键数值与推荐
- 初始诊断后24个月内疾病进展应被视为预后不良的强指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a rare peripheral B-cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab- and cytarabine-based immunochemotherapy regimens, the prognosis of the disease has changed dramatically over the last two decades. To assess the real-world survival of patients with MCL, we used a population-based cohort of 564 patients with MCL who were diagnosed and treated between 2000 and 2020. Patient data were collected from seven Finnish treatment centres and one Spanish treatment centre. For the entire patient population, we report a 2-year overall survival (OS) rate of 77%, a 5-year OS of 58%, and a 10-year OS of 32%. The estimated median OS was 80 months after diagnosis. MCL is associated with increased mortality across the entire patient population. Additionally, we assessed the survival of patients after MCL relapse with the aim of establishing a cut-off point of prognostic significance. Based on our statistical analysis of survival after the first relapse, disease progression within 24 months of the initial diagnosis should be considered as a strong indicator of poor prognosis.
引用
- Harmanen M, Hujo M, Sund R, et al. Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. Br J Haematol. 2022. PMID: 36513500. doi:10.1111/bjh.18597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。